Globestar Therapeutics Corporation (PK) (GSTC) Share Price

load zone...when filing hits and pink current look for more updates

T minus 8 days until we go expert

Placing bets to see what people think comes into this shell depending on if we get current lol.

1) Crypto Miner
2) Gem Mine
3) Precious Metal Mine
4) Covid Scam
5) cyber security

Pick your poison

0003 thinning..HE GETS THIS CURRENT THIS WILL RUN LIKE A GAZELLE being chased by a bunch of lions

0003 and noones pumping? where are the AQUATRADERS....you all loved this at .02
time to AVERAGE DOWN AGAIN
market cap 400,000 dollars...crazy

I wouldn’t be shocked to see Jim looked into

how can he not be serious...GSTC goes to gray sheets its GAME OVER and I'm sure there will be many lawsuits or worse.
he should of sold the company...0002 is totally f-ing a slap in the face to all shareholders that supported him....

LMAO!!!!
Sure ya did Buddy!
And STILLLLLLLLLLLLLLL..... 100% right about $GSTC.... while YOU have been 1000% WRONG!!!!!
Or as "Lady Killer" would say.... "WAY WRONG!!!!"

P.S.
You are a TERRIBLE pumper!!

Lol wowwwww

The money wasted here by Jim should be looked into

And we are now bottom heavy in the trips. Gonna take a 200 mil volume day to get us out of trip 0’s

If we do go current. We will most likely see one of the famous OTC scams be put in place. The MS idea is dead, we all have to accept that. You cant fund a clinical trial at .0003

So we’re looking at either:

1. Covid scam
2. Another “biopharma play”
3. Precious metal miner
Or
4. Crypto miner

Pick your poison lol

bidding 0003 to average down 1 more time. 50/50 better then 0

I sent Jim a link to NIH non-dilutive financing programs that they may be able to use. If he is serious, he would be all over that. We will see.

Actually I take that back. Didn’t realize we gad a 10/02 update. Still $15k in debt locked in, you’re right. I’ll lighten up and give this a 50% chance of going current.

You’ll see about a 250 mil increase on the next update……. If there is one lol

Debt holders ran for the exits already. Lights are out. There’s noone home

nah any and all debtholders will come through as I'm sure the filings are ready.way too much money involved to let it go.
Jim should sell a kidney not to lose this now if no one lends him more $$$$$$
0004 is worth the gamble traders

I think we can all agree the nail is in the coffin. Management failed miserably here and misappropriated funds. Things are going to get real interesting when the subpoenas start to go out.

0003 wtfffffffffffffffffffffffffff....that 00017 debtholder is a scumbag

only 16m on ask..what a POS the 00017 debtholder is.

hopefully that POS/ahole regrets selling 0004. I never thought possible this low floater with only 1.2b out would hit 0004

Someone still running for the gates and taking what they can get……

wasn't the patent renewed till 2035 or something?

Jim always finds cash and like I said.....losing this TIKKER to EXPERT market would WIPE HIM OUT ALSO AND HE WILL LOSE EVERYTHING INCLUDING 600k-1m what the Chinese would pay for GSTC

Well the company has no cash so we’re in a bit of a pickle

fwiw the market cap here at 0005 is only 600k.....the TIKKER is worth 600k-1million......
Jim would be the biggest IDIOT on the planet if he let this go to EXPERT market....

He would have netter chances licensing his patent to a pet rock.

and where will FABRIZI go? his best chance of funding is via GSTC.

and GSTC still has the license and why are you not pumping now at 0005 as you were since .02?????????

Well Welll Wellllllll......
Ready to tell everyone how YOU lied? YOU should apologize to EVERYONE.
YOU have known allllll along.

I guess we will see.i try to remain positive as I and many here bought from .02 down to 0004

GlobeStar Therapeutics owns the exclusive global license from the inventors, who are based in Italy. GlobeStar Therapeutics is initiating discussions with the FDA on clinical trial design in preparation for FDA submission and approval pathway.
https://www.otcmarkets.com/filing/html?id=15463373&guid=2OL-kpxRYywfJth

Notice how it doesn’t say “acquires patent”

Sorry. This is not the case. He acquired the license for commercialization.

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis

Lol no they didn’t. They got rights to commercialization. That is all.

SOAN BOUGHT OUT FABRIZI YEARS AGO.

Now what happens when Fabrizio decides to pull his patent because management failed on all ends?

Yea buddy, posting a patent isn’t gonna get people to buy lol.

https://www.wipo.int/patents/en/faq_patents.html
PATENT GRANTED 2020---good for 20 years!

date of PATENT---april 7 2020
ignore the BS longs.
https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/10610592?requestToken=eyJzdWIiOiJmMWM0YjdlNC02N2RjLTRiMWUtYWEzOC04YzFlN2I5NDJhZWUiLCJ2ZXIiOiIwNDhjMzdlYS1kZDRkLTRkZGUtYWY1My0yMjMyMzgxNzU5NTkiLCJleHAiOjB9

GSTC a clinical stage pharmaceutical company, is developing a patented formulation for treating Multiple Sclerosis (MS). Recently, GSTC participated in the 29th annual Race to Erase MS Gala, enhancing its visibility among MS experts and potential collaborators. The company is conducting promising studies, including a pharmacokinetics study and initial clinical trials initiated in Italy, where all participants reported improvements in mobility and control after treatment. The global market for MS drugs is projected to reach $33.46 billion by 2026.

The problem isn’t the patent. The problem is misappropriation of funds when it only costs $5K to file but $25K is raised every quarter. And that’s on the low end. Some quarters up to $80K was raised if you go back to 2022.

https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/10610592?requestToken=eyJzdWIiOiJmMWM0YjdlNC02N2RjLTRiMWUtYWEzOC04YzFlN2I5NDJhZWUiLCJ2ZXIiOiIwNDhjMzdlYS1kZDRkLTRkZGUtYWY1My0yMjMyMzgxNzU5NTkiLCJleHAiOjB9

https://www.stocktitan.net/news/GSTC/globe-star-therapeutics-enters-into-definitive-agreement-with-1ay4j9j6jqfs.html

The company holds exclusive worldwide rights to all associated patents and patent applications, including U.S. Patent #10610592.

GSTC is a clinical-stage pharmaceutical company dedicated to pioneering new treatments for Multiple Sclerosis (MS) and other neurological diseases. GSTC's flagship initiative, Project Amethyst™, focuses on a patented compound aimed at treating neurodegeneration caused by MS. The company holds exclusive worldwide rights to all associated patents and patent applications, including U.S. Patent #10610592.

Among the company's notable collaborations is an agreement with Advanced Innovative Partners (AIP), a clinical-stage entity specializing in therapeutic and diagnostic radiopharmaceuticals. This partnership is geared towards the design and execution of comprehensive clinical trials for Project Amethyst™, leveraging AIP's global network of medical institutions and expertise in clinical trials. Additionally, GSTC has entered into a definitive agreement with SMI HealthCare LLC (SMIHC) to manage clinical trials, regulatory filings, manufacturing, sales, and distribution across India, Southeast Asia, Africa, and the Middle East.

Initial clinical studies in Italy involving 150 volunteers demonstrated promising results, with substantial improvements in motor and bladder control among MS patients. The collaboration with SMIHC aims to further these studies in India, a region identified as a cost-effective hub for conducting high-quality clinical trials for FDA and EU regulators.

Financially, GlobeStar is navigating the complexities of funding these extensive clinical trials and regulatory approvals. The company reported a slight increase in operating expenses in its latest quarterly financials, reflecting its active pursuit of these ambitious projects.

GSTC's plan involves staging clinical trials, starting with a pharmacokinetic study in Europe and India to understand the drug's behavior in the human body. This will lay the groundwork for subsequent clinical trials, expected to last around three to six months. Positive outcomes could expedite regulatory approvals in multiple regions, including North America and Europe.

With the global and North American MS drug markets projected to grow significantly, GlobeStar Therapeutics is positioning itself to capture a substantial market share. The company's mission extends beyond MS, with potential future applications in treating other neurodegenerative and chronic illnesses.

GUYS!!!!
What happened to allllllll that super solid "DD" the waterboy pinned at the top of this board????
Did he forget to remind the $GSTC CEO to renew the patent again??? HOWWWWW on earth was THAT alone not a HUGE red flag for someone with such SUPER DUPER OUTSTANDING "DD" skills?

Oh really? Hmm so he raises $25k every quarter and it only costs $5K to file. Wonder where the money is?